Routinely used predictive features, including clinicopathological parameters (age, tumor size, lymph node status, and histological grade) and biomarkers (ER, PR, and HER2) are insufficient for personalized clinical decisions in BC patients (3). This evidence concerns the gene ERBB2 and neoplasm.